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In a Japanese study, cyclin-dependent kinase (CDK) based risk determined by CDK 1 and 2 activities was associated with risk of
distance recurrence in early breast cancer patients. The aim of our study was to validate this risk categorization in European early
breast cancer patients. We retrospectively analyzed frozen breast cancer specimens of 352 Dutch patients with histologically
confirmed primary invasive early breast cancer. CDK-based risk was determined in tumour tissues by calculating a risk score (RS)
according to kinases activity and protein mass concentration assay without the knowledge of outcome. Determination of CDK-based
risk was feasible in 184 out of 352 (52%) tumours. Median follow-up of these patients was 15 years. In patients not receiving systemic
treatment, the proportions of risk categories were 44% low, 16% intermediate, and 40% high CDK-based risk. These groups
remained significant after univariate and multivariate Cox-regression analysis. Factors associated with a shorter distant recurrence-free
period were positive lymph nodes, mastectomy with radiotherapy, and high CDK-based risk. There was no significant correlation with
overall survival (OS). CDK-based risk is a prognostic marker of distance recurrence of patients with early breast cancer. More
validation would be warranted to use of CDK-based risk into clinical practice.
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Breast cancer is the most commonly occurring cancer and the
leading cause of cancer death in women in the Western world
(Parkin et al, 2005). In addition to local therapy, systemic
treatment improves disease-free and overall survival (OS) in
patients with early breast cancer (Early Breast Cancer Trialists’
Collaborative Group, 2005). Based on traditional prognostic
markers, such as age, tumour grade/size and nodal status, patients
are classified into different risk groups to determine who will
receive systemic treatment (Goldhirsch et al, 2007). However,
breast cancer can recur in low-risk patients not receiving systemic
treatment, resulting in a poor clinical outcome. This indicates that
these conventional prognostic markers are not yet optimal for risk
assessment. Although several new tumour-related biological
parameters are investigated, none of these has been introduced
in standard clinical practice so far (Annecke et al, 2008; Cardoso
et al, 2008; Sparano and Paik, 2008).
One relevant characteristic of tumours is their aggressiveness in
proliferation, which is evaluated by such biological indicators as
3H-thymidine uptake, DNA-analysis, mitotic activity index (MAI)
and Ki-67 expression. These approaches are not highly useful in
clinical practice, because of technical and performance instabil-
ities. It was shown that overexpression of cyclins, which bind and
activate cyclin-dependent kinases (CDKs), as well as inactivation
of CDK inhibitors such as p21WAF1 and p27Kip1, which inhibit
CDK activities, correlates with prognosis in a variety of
malignancies (Gillett et al, 1994; Gramlich et al, 1994; Gansauge
et al, 1997; Sutter et al, 1997; van Diest et al, 1997; Nakashima et al,
2000; Sjostrom et al, 2000; Takano et al, 2000; Ishihara et al, 2005).
Therefore, direct measurement of CDK activity could provide more
reliable clinical information about the prognosis than used
molecular pathological parameters.
On the basis of these considerations, an assay system was
developed that can directly measure the activity and expression of
CDK1 and CDK2 in a routine laboratory test (SA; the kinases
activity divided by the protein mass concentration) was established
(Ishihara et al, 2005). The clinical performance of the system was
first evaluated in a Japanese retrospective study in 284 early breast
cancer patients with a median follow-up of almost 5 years (Kim
et al, 2008). It was found that CDK-based risk derived from the SA
of CDK1 and CDK2 was associated with risk of relapse. However,
the procedure to determine this CDK-based risk is complicated
and intuitive. Therefore, the data of the last Japanese study was re-
evaluated to define a risk score (RS), which quantitatively indicates
the risk for recurrence.
The aim of our study was to validate the prognostic value of the
modified CDK-based risk recurrence model in a European patient
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spopulation and to examine if CDK-based risk is correlated with
established prognostic factors. In turn, these results may be used to
enable better risk identification for early breast cancer patients as
the basis for better risk adapted individualised adjuvant systemic
treatment decisions.
MATERIALS AND METHODS
Patients
A consecutive series of patients with histologically confirmed
invasive early breast cancer that received primary surgical
resection in the Leiden University Medical Centre between 1985
and 1996 was used. Patients with an earlier history of cancer (other
than basal cell carcinoma or cervical in situ carcinoma), bilateral
tumours or a secondary tumour other than breast cancer, were
excluded. The following data were available: age at diagnosis,
histological type, TNM stage, local and systemic therapy,
locoregional and distant recurrence, second primaries, and OS.
All tumours were regraded by one pathologist (VS). Approval was
obtained from the LUMC Medical Ethics Committee.
Sample preparation
Tumour tissue was dissected from the surgical resection,
immediately embedded in optimal cutting temperature (OCT)
compound, and stored at  801C. Ten to 20 sections of 100mm
thickness were cut from the embedded tissue with a cryostat and
subjected to CDK analysis as described below. To analyze the
influence of OCT contamination to the assay system, the OCT
content at the surface of the cryosection was recorded as a
percentage.
Determination of CDK-specific activities
The system to measure the CDK SA is named C2P
s (Sysmex, Kobe,
Japan). In brief, lysate of frozen material was applied to a well of a
dot-blot device. Expression of CDKs was detected quantitatively by
sequential reactions with primary anti-CDK antibodies, biotinylated
anti-rabbit antibodies, and fluorescein-labelled streptavidin. To
measure kinases activity, each CDK molecule was immunoprecipi-
tated from the tissue lysate. The thiophosphate of ATP-gSw a s
transferred to the protein substrate during the on-bead kinases
reaction. The introduced thiophosphate was labelled further with 5-
iodoacetamidofluorescein and blotted onto a polyvinylidene fluoride
membrane. The kinases activity was determined by measuring the
fluorescence intensity of the blot.
CDK SA was calculated as kinases activity (mAU per ml lysate)
divided by its corresponding mass concentration (EU per ml
lysate). Both of AU (CDK activity unit) and EU (CDK expression
unit) were defined as the equivalent expression and activity of 1ng
of recombinant active CDK molecule, respectively.
Risk score
In the previous Japanese study, the distribution of CDK1SA
and CDK2SA was moderately related (r¼0.501, log
(CDK2SA)¼0.533log (CDK1SA)þ1.225), and the aberration from
this relationship correlated with the rate of recurrence (Kim et al,
2008). Besides, recurrences were frequently observed in patients
with a tumour with higher CDK1SA. The extent of the aberration
was quantified as the ratio of CDK2SA relative to CDK1SA
(CDK2SA/CDK1SA). The rate of recurrence monotonically in-
creased with increasing ratio of CDK2SA/CDK1SA or CDK1SA.
These plots approximated logistic curves (Equations (1) and (2))
and the RS was defined by combining these relational equations.
Setting the cutoff value with the cases of the Japanese study; 40% of
the patients in the high RS group, showed a significantly lower
recurrence-free survival rate in 5 years after surgery (84.0%; 9 out
of 58) compared with 40% of the low RS group (96.5%; 2 out of 58)
(P¼0.009). Less than 20% of the patients were regarded as an
intermediate RS group.
The risk for recurrence was quantified as an RS.
RS ¼ Eq:1 Eq:2
0:25=ð1 þ Expð ðx   1:0Þ 6Þ; x ¼ logðCDK2SA=CDK1SAÞð 1Þ
0:20=ð1 þ expð ðy   1:6Þ 7Þ; y ¼ logðCDK1SAÞÞ: ð2Þ
Exclusion from statistical analysis
Severe blood contamination into the tissue lysate impairs the
accuracy of the expression analysis. To avoid this problem,
the extent of contamination is routinely visually quantified
by comparing the redness of the lysate with a standard colour
bar, which ranges from dark to faint and is graded 1–10;
tissue with grade 1–3 are excluded from analysis. Another
sample was excluded due to assay failure. Cellularity of the tissue
was judged in the C2P system by the expression of CDKs because
the molecule is expressed ubiquitously and continuously during
the cell cycle. All samples whose CDK1 or CDK2 expression was
below the detection limit of the system (3.2Uml of lysate for CDK1
and 0.08Uml of lysate for CDK2) were judged to contain an
insufficient number of cells for the system and were excluded from
the analysis.
Statistical analysis
Statistical analyses were performed using the statistical package
SPSS for Windows 15.0. (SPSS Inc., Chicago, IL, USA). Descriptive
data are given as mean (s.d.) or median (range). The relationship
between CDK-based risk groups and established prognostic factors
were investigated using Pearson’s w
2 test. All testing was two-tailed
with 0.05 as level of significance (Altman et al, 2000).
Distant Recurrence-Free Period (DRFP) was defined as the time
from surgery up to the first date of distant recurrence. Overall
Survival was defined from the date of surgery up to the date of
death due to any cause. To examine if CDK-based risk correlates
with DRFP and OS, univariate Cox analysis was performed.
Multivariate analyses were performed using the Cox-proportional
hazards model entering CDK with other significant variables
(defined as those with Po0.1 on univariate analysis). Distance
Recurrence Free Period rates are reported as cumulative incidence
functions, after accounting for death as competing risk (Putter
et al, 2007).
Role of funding source
This retrospective study was sponsored by an unrestricted
educational grant of Sysmex (Kobe, Japan).
RESULTS
Patients
A total of 803 patients with early breast cancer were treated
with primary surgery in our centre during the study period. Frozen
material was available from 352 out of 803 (44%) patients. Median
follow-up of patients alive at last follow up was 15 years (range,
6–21). Clinicopathological and treatment characteristics are
shown in Table 1. There were minor differences between patients
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CDK determination was feasible in those patients who had larger
tumours (70 vs 60%), had slightly more node-positive disease
(53 vs 47%) and were less treated with breast conserving surgery
(24 vs 35%). In general, there were no large differences in survival
characteristics.
Table 1 Patients/tumour/treatment characteristics.
Patients with fresh
frozen tumour
tissue available
Same as previous column,
in which CDK determination
was feasible
Same as previous column,
but patients received
no systemic treatment
N % N % N %
Age (years)
o40 28 8 16 9 7 7
4 0 – 5 0 9 02 64 52 5 2 1 2 2
5 1 – 6 0 7 42 13 92 1 1 9 2 0
460 160 46 84 46 50 52
Tumour size
o 20mm 142 40 55 30 38 39
X20mm 210 60 129 70 59 61
Tumour grade
I 5 71 72 21 2 1 3 1 4
II 163 48 86 48 49 53
III 120 35 71 40 31 33
Histological type
Ductal 318 94 169 94 88 95
Lobular 20 6 9 5 4 4
Other 2111 1 1
Nodal stage
Negative 186 53 87 47 76 78
Positive 166 47 97 53 21 22
Oestrogen receptor
Positive 87 39 52 43 24 36
Negative 137 61 70 57 42 64
Progesterone receptor
Positive 104 46 65 52 33 49
Negative 123 54 60 48 34 51
Ki-67 expression
o5 143 63 85 69 47 71
X5 8 43 73 93 2 1 9 2 9
HER2
0+/1+ 198 88 101 84 53 82
2+/3+ 28 12 20 17 12 19
Vascular invasion
Negative 287 84 149 83 81 86
Positive 54 16 31 17 13 14
Local treatment
MST without radiotherapy 151 43 86 47 58 60
MST with radiotherapy 78 22 53 29 14 14
BCS without radiotherapy 5121 0 0
BCS with radiotherapy 118 34 43 23 25 26
Systemic treatment
Chemotherapy alone 65 19 42 23 0 0
Hormonal therapy alone 66 19 36 20 0 0
Both 15 4 9 5 0 0
None 206 59 97 53 97 100
Survival
Locoregional recurrence 44 13 21 11 10 10
Distant recurrence 146 42 85 46 37 38
Death 197 56 110 60 56 58
Total 352 100 184 100 97 100
BCS¼breast conserving surgery; MST¼mastectomy. The numbers and percentage are calculated on available data. Missing data are not shown. First of all patients treated in the
Leiden University Medical Centre between 1985 and 1996 with available fresh frozen tumour tissue, second of patients in which cyclin dependent kinase (CDK) determination
was feasible, third of patients in which CDK-determination was feasible and who were only treated with local therapy.
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Determination of CDK-based risk by RS was successful in 52% of
patients (184 out of 352). In 48% of cases it was not possible due to
extreme blood contamination (n¼33), OCT contamination (n¼45),
assay failure (n¼1) or low cellularity (n¼79). According to CDK-
based risk, 41% (n¼76) were classified as low, 13% (n¼23) as
intermediate, and 46% (n¼85) as high CDK-based risk.
CDK-based risk and clinicopathological parameters
Correlation between established clinicopathological variables and
CDK-based risk are shown in Table 2. There was a significant
association between CDK-based risk and age, nodal status, and
grade. High CDK-based risk was increasingly evident in younger
patients, node-positive disease and grade-III tumours. There was
also an association between histological type and CDK-based risk;
however, most tumours were ductal carcinomas. No significant
association was found between CDK-based risk and tumour size,
hormonal receptors, Ki-67 expression, HER2 expression, and
vascular invasion.
CDK-based risk and survival
Patients with tumours classified as low or intermediate CDK-based
risk showed higher DRFP rates than patients with tumours with
high CDK-based risk (intermediate and high-risk group vs low-risk
group; hazard ratio (HR) 1.50; 95% confidence intervals (CI)
0.74–3.05 and HR¼2.04; 95% CI 1.26–3.28, respectively,
overall P-value¼0.014) (Figure 1). If we compare the low vs high
CDK-based risk group concerning DRFP at 5, 10 and 15 years, 95%
CIs are 0.04–0.34, 0.07–0.38 and 0.06–0.38, respectively. Patients
with a low CDK-based risk have a better OS than patients with a
high CDK-based risk, although this difference is not statistically
significant (intermediate and high-risk group vs low-risk group;
HR¼0.94; 95% CI 0.49–1.79 and HR¼1.37; 95% CI 0.92–2.05,
respectively, overall P-value¼0.216).
Table 2 Association between cyclin dependent kinase (CDK)-based risk groups and well established prognostic factors
CDK-based risk CDK-based risk CDK-based risk
Low Intermediate High
N % N % N % P-value
Age (years) 0.022
o40 3 19 1 6 12 75
4 0 – 5 0 1 32 9 4 92 86 2
50–60 20 51 6 15 13 33
460 40 48 12 14 32 38
Tumour size 0.261
o20mm 23 42 10 18 22 40
X20mm 53 41 13 10 63 49
Nodal stage 0.01
Negative 43 49 14 16 30 35
Positive 33 34 9 9 55 57
Tumour grade 0.01
I 8 36 4 18 10 46
II 44 51 14 16 28 33
III 23 33 5 7 43 61
Histological type 0.046
Ductal 69 41 20 12 80 47
Other 6 60 3 30 1 10
Oestrogen receptor 0.123
Negative 17 33 6 12 29 56
Positive 32 46 12 17 26 37
Progesterone receptor 0.183
Negative 21 32 11 17 33 51
Positive 29 48 7 12 24 40
Ki-67 expression 0.387
o5 3 74 41 21 43 64 2
X5 12 31 6 15 21 54
HER2 0.444
Negative 40 40 16 16 45 45
Positive 9 45 1 5 10 50
Vascular invasion 0.84
Negative 62 42 20 13 67 45
Positive 13 42 3 10 15 48
High CDK-based risk is higher in younger patients, node-positive disease and grade III tumours.
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Cox analysis (Table 3). In multivariate Cox-regression analysis,
positive nodal status, mastectomy with radiotherapy, no systemic
treatment, and high CDK-based risk were predictive for a
decreased DRFP.
Prognostic value of CDK-based risk
To examine the prognostic value of CDK-based risk, we excluded
all patients who received systemic treatment. This patient
population could be categorised by CDK-based risk as: low 44%
(n¼43 out of 97), intermediate 16% (n¼15 out of 97), and high
40% (n¼39 out of 97). Patients with tumours classified as low or
intermediate CDK-based risk showed higher DRFP rates than
patients with tumours with high CDK-based risk (intermediate and
high-risk group vs low-risk group; HR 1.40; 95% CI 0.49–3.99 and
HR¼2.31; 95% CI 1.13–4.73, respectively, overall P-value¼0.068)
(Figure 2). If we compare the low vs high CDK-based risk group,
differences in DRFP at 5, 10, and 15 years are 19, 28 and 26%,
respectively. Accompanying 95% CIs for these differences are
0.01–0.39, 0.06–0.48, and 0.01–0.47, respectively (Figure 2). There
was no statistical difference between these groups concerning OS
(intermediate and high-risk group vs low-risk group; HR¼1.06;
95% CI 0.47–2.37 and HR¼1.44; 95% CI 0.81–2.54, respectively,
overall P-value¼0.432).
Univariate and multivariate Cox-regression analysis showed that
CDK-based risk groups remained statistically significant (Table 4).
Factors associated with a shorter DRFP were positive lymph nodes,
mastectomy with radiotherapy, and high CDK-based risk.
DISCUSSION
In our European patient population with early breast cancer, the
CDK-based risk was validated. Multivariate analysis showed that
CDK-based risk was an independent significant prognostic factor
for DRFP in all patients and in patients treated with local therapy
only. CDK-based risk is a tangible prognostic marker for DRFP.
Currently, risk-assessments with various prognostic and pre-
dictive markers are used for indication of systemic treatment, like
tumour grade and nodal status for general systemic treatment
choice, hormonal receptors for hormonal treatment, and HER2
expression for immunotherapy. However, these assessments are
insufficient for optimal therapeutic decision, especially when
applied to node-negative early breast cancer patients. Only few
of these patients are considered at such a low-risk of relapse that
systemic therapy can be avoided. At the same time, not all patients
at high-risk experience a recurrence. Therefore, there is demand
for more accurate prognostic markers for a more tailored
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Figure 1 Distant recurrence-free period according to CDK-based risk.
Patients with a low CDK-based risk have a longer distant recurrence-free
period than patients with a high CDK-based risk.
Table 3 Univariate and multivariate analysis of distant recurrence-free
period (DRFP). Independent factors for a shorter DRFP are positive nodal
status, mastectomy with radiotherapy, no systemic treatment and
intermediate/high CDK-based risk
Univariate analysis Multivariate analysis
Characteristics N HR 95% CI P-value HR 95% CI P-value
Age (years)
o50 61 1.00 0.720
X50 123 0.92 0.59–1.44
Tumour size
o20mm 55 1.00 0.013 1.00 0.660
X20mm 129 1.96 1.15–3.34 1.21 0.52–2.84
Nodal status
Negative 87 1.00 0.000 1.00 0.004
Positive 97 3.08 1.92–4.95 2.86 1.40–5.87
Grade
I/II 108 1.00 0.231
III 71 1.30 0.85–2.01
Histological type
Ductal 169 1.00 0.967
Other 10 1.02 0.41–2.52
Local therapy
MST RT 86 1.00 0.000 1.00 0.003
MST+RT 53 2.35 1.46–3.78 2.67 1.36–5.25
BCT 45 0.80 0.34–1.46 0.73 0.31–1.73
Oestrogen receptor
Negative 52 1.00 0.222
Positive 70 1.40 0.81–2.42
Progesterone receptor
Negative 65 1.00 0.512
Positive 60 0.84 0.51–1.40
Ki-67 expression
o5 85 1.00 0.100 1.00 0.618
X5 39 1.56 0.92–2.64 1.15 0.66–2.01
HER2 expression
Negative 101 1.00 0.873
Positive 20 0.94 0.46–1.93
Lymphagio invasion
Negative 149 1.00 0.039 1.00 0.699
Positive 31 1.70 1.03–2.82 1.15 0.56–2.38
Systemic therapy
No 97 1.00 0.020 1.00 0.011
Yes 87 1.66 1.08–2.56 0.40 0.20–0.81
CDK-based risk
Low 76 1.00 0.014 1.00 0.023
Intermediate 23 1.50 0.74–3.05 1.89 0.82–4.39
High 85 2.04 1.26–3.28 2.36 1.27–4.37
BCT¼breast conserving therapy; MST¼mastectomy; RT¼radiotherapy.
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to identify indications for the best therapy.
In 2007, the American Society of Clinical Oncology Committee
recommended the following markers in clinical practice in patients
with early breast cancer: ER, PgR, HER2, urokinases plasminogen
activator (uPA), plasminogen activator inhibitor-1 (PAI-1), and
certain genes detected with multiparameter gene expression assays
(Harris et al, 2007). ER, PgR, and HER2 are widely used and should
be determined in every patient with early breast cancer. uPA and
PAI-1 are key factors in efficient focal proteolysis, adhesion, and
migration of tumour cells (Andreasen et al, 1997; Schmitt et al,
1997; Bouchet et al, 1999; Duffy, 2002; Harbeck et al, 2002).
Currently, the prognostic value of uPA and PAI-1 are being
examined in the prospective Node-Negative Breast Cancer III
(NNBC 3)-Europe Trial (Annecke et al, 2008). As another
prognostic tool, the value of microarray-based prognostics and
feasibility of its clinical application into clinical practice is in the
process of evaluation by two major trials. The first prospective trial
is the European Microarray in Node-Negative Disease May Avoid
Chemotherapy Trial evaluating MammaPrint (Agendia, Amsterdam,
the Netherlands), a 70-gene expression profile, in node-negative
early breast cancer patients (van de Vijver et al, 2002; Cardoso
et al, 2008). Its American counterpart, the Trial Assigning
Individualized Options for Treatment, is aimed at validating
Oncotype DX (Genomic Health, Redwood City, CA, USA),
a 21-gene assay, likewise in node-negative patients (Palli et al,
1999; Sparano and Paik, 2008). The Oncotype DX profile can be
determined using paraffin-embedded breast tissue; the Mamma-
Print profile makes use of fresh frozen material. Both profiles must
be analysed centrally; no ready-to-use kit is available to determine
the profile in local hospitals.
In the ideal clinical trial setting, the above-mentioned prog-
nostic factors, including CDK-based risk, should be determined
in the same tumour sample to determine the best marker
combination for optimal treatment decisions. Unfortunately it is
not likely that such a large, long-lasting and costly trial will be
actualised.
From our results, it was shown that validation of CDK-based
risk was feasible for European patients even though the RS was
determined in Japanese patients. Despite the difference between
the cohorts, it may be concluded that CDK-based risk is a new
prognostic factor. However, before this CDK-based risk can be
used in daily clinical practice, several aspects have to be
considered. First issue is the high proportion of exclusion cases
in this study; in almost 50% of tumours it was not feasible to
determine CDK-based risk. This was related to weaknesses of the
assay system, because the accuracy of the expression analysis is
influenced by blood and OCT contamination. However, we believe
these issues are not significant problems anymore. A washing step
before tissue lysis markedly improved the efficacy of CDK
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Figure 2 Distant recurrence-free period according to CDK-based risk in
patients treated with local therapy only. Patients with a low CDK-based risk
have a longer distant recurrence-free period than patients with a high CDK-
based risk.
Table 4 Univariate and multivariate analysis of distant recurrence-free
period (DRFP) for patients receiving only local treatment to examine the
real prognostic value of CDK-based risk
Univariate analysis Multivariate analysis
Characteristics N HR 95% CI P-value HR 95% CI P-value
Age (years)
o50 28 1.00 0.237
X50 69 1.58 0.74–3039
Tumour size
o20mm 38 1.00 0.065 1.00 0.582
X20mm 59 1.98 0.96–4.10 1.26 0.56–2.83
Nodal status
Negative 76 1.00 0.000 1.00 0.004
Positive 21 3.50 1.81–6.77 2.70 1.37–5.34
Tumour grade
I/II 62 1.00 0.467
III 31 1.28 0.66–2.51
Histological type
Ductal 88 1.00 0.352
Other 5 0.39 0.05–2.85
Local therapy
MST-RT 58 1.00 0.000 1.00 0.000
MST+RT 14 4.98 2.36–10.51 4.71 2.06–10.79
BCT 25 0.53 0.21–1.36 0.46 0.16–1.29
Oestrogen receptor
Negative 24 1.00 0.788
Positive 42 1.12 0.50–2.48
Progesterone receptor
Negative 33 1.00 0.934
Positive 34 0.97 0.47–2.01
Ki-67 expression
o5 47 1.00 0.165
X5 19 1.72 0.80–3.70
HER2 expression
Negative 53 1.00 0.166
Positive 12 1.84 0.78–4.37
Vascular invasion
Negative 81 1.00 0.049 1.00 0.057
Positive 13 2.20 1.00–4.84 2.32 0.97–5.51
CDK-based risk
Low 43 1.00 0.068 1.00 0.018
Intermediate 15 1.40 0.49–3.99 2.33 0.76–7.15
High 39 2.31 1.13–4.73 2.99 1.40–6.39
BCT¼breast conserving therapy; MST¼mastectomy; RT¼radiotherapy. Indepen-
dent factors for a shorter DRFP are positive nodal status, mastectomy with
radiotherapy and intermediate/high CDK-based risk.
CDK-based risk validation
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not shown). The crucial issue of the exclusion is low cellularity
measured by CDK expression. In our study, 22% (79 out of 352)
were excluded because of low cellularity. The Japanese retro-
spective study, which used snap-frozen tissues, found a lower rate
of low cellularity (11%, unpublished data), and this value was
judged as a clinically practical value. One challenge is to carefully
determine the sufficient amount of a cryosection to apply CDK-
based risk on OCT-embedded samples. Secondly, to enable general
use for broad application, a feasible ready-to-use kit should be
devised including the cell cycle profile system.
In the association analysis of CDK-based risk to clinicopatho-
logic factors, we found significant associations between the CDK-
based risk and age, nodal status, and grade. Unexpectedly, a
statistically significant association was not observed between
CDK-based risk and Ki67 expression, known as a proliferation
marker of tumour tissues. This discrepancy may be because of the
technical issue of Ki67 immunohistochemistry procedure; the lack
of an international standardisation method for antigen retrieval,
staining procedures and scoring methods. To further address the
significance of CDK-based analysis, cell biological interest for rate
of cell proliferation, cell cycle distribution (G1/S/G2M-phase),
check point regulation, and CDK-mediated cell death should be
examined both in vitro and in vivo.
In conclusion, our results showed that CDK-based risk is
prognostic for DRFP in patients with early breast cancer, also after
correction with other prognostic factors. Therefore, further studies
are justified to develop this as a marker for more tailored
treatment of early breast cancer patients.
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